# Pharmacogenomic Data Submissions:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenomic-data-submissions-guidance-for-industry/1d145832-ef9c-4b45-b5aa-8c828660e984

> FDA guidance document: Pharmacogenomic Data Submissions:  Guidance for Industry. Issue date: March 01, 2005. Get complete insights and analysis.

---

## Details

- Title: Pharmacogenomic Data Submissions:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2005-03-01
- Last Changed: 2020-04-27
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2003-D-0031">FDA-2003-D-0031</a>

## Related Documents

- [E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/e14-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs/c83f1589-7be1-4064-93e8-eedcbfd73f95)
- [Premarketing Risk Assessment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/premarketing-risk-assessment-guidance-for-industry/232a7962-0cba-49be-a6b4-356c35b5f91f)
- [S8 Immunotoxicity Studies for Human Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/s8-immunotoxicity-studies-for-human-pharmaceuticals/216b9605-e0e0-4dd4-a10b-a51326a268f5)